Biocartis announces that its researchers, in collaboration with researchers at the Wellcome Trust Sanger Institute and at Philips Research, are developing a novel workflow for extraction and amplification & detection of tumor DNA on Biocartis diagnostic platforms. Biocartis retains its full IP rights, with access to IP created during the scope of this collaboration. The availability of this test is expected to have a major impact on personalizing treatment of tumors, increasing the quality of clinical care and the quality of life for the patient. Individual decisions on treatment duration and intensity will be in reach and ultimately, this could allow drugs to be targeted to only those patients who show meaningful response, reducing unnecessary side-effects and improving effectiveness.
Dr Patrick van den Bogaard, Director of Life Science Research at Biocartis SA comments: “The system will use disposable, microfluidic cartridges with digitally encoded micro particles for the rapid and sensitive detection of multiple DNA samples. The test aims to be highly specific and sensitive, being able to isolate and detect just a few molecules of tumor DNA per ml of blood. To implement such tests in a real-world healthcare system requires development of fully automated, high multiplexing diagnostic instruments and technology which is the core focus of Biocartis.”
MRC Technology and Biocartis initiate development of liquid biopsy test for breast cancer
MRC Technology and Biocartis Group NV announced a partnership to develop selected molecular diagnostic tests for use on Biocartis' fully automated Idylla(TM) platform. MRCT aims to move promising medical research forward into patient treatments and diagnostics and has been involved in helpi ... more
Biocartis announces its new CEO
Biocartis Group announces Herman Verrelst as its new Chief Executive Officer (CEO), effective as of August 2017. Herman is a seasoned executive and serial entrepreneur with a proven international commercial track-record in molecular diagnostics. Herman currently holds the position of Vice P ... more
Merck and Biocartis to Collaborate
Merck announced that it has signed a collaboration agreement with Biocartis for the development and commercialization of a new liquid biopsy RAS biomarker test for patients with metastatic colorectal cancer (mCRC). The test will be developed on Biocartis’ innovative, fully automated molecul ... more
Researchers from Illumina, Inc. and the Wellcome Trust Sanger Institute have used Illumina's next generation sequencing technology to create a draft genome sequence for the endangered Tasmanian devil, and will use this to find genetic mutations in the transmissible cancer that is ravaging ... more
Oxford Gene Technology successfully completes world's largest copy number variation study
Oxford Gene Technology (OGT) has successfully completed processing more than 20,000 samples that have been generated by the Wellcome Trust Case Control Consortium (WTCCC), the world’s largest CNV study involving a collaboration of 24 human geneticists. The project analysed DNA samples from ... more
Novel method to reveal drug targets
Wellcome Trust Sanger Institute scientists have developed a new large-scale method to identify the interactions between proteins that are a major target for therapeutic intervention. The novel method can identify the weak, short-lived interactions that are characteristic of cell responses t ... more
Philips enters into collaboration with Janssen to develop new handheld blood test
Royal Philips announced that it has entered into a multi-year development agreement with Janssen Pharmaceutica N.V.. The collaboration aims to develop a new handheld blood test to provide doctors with a novel tool to improve the care of patients with neuropsychiatric disorders.The collabora ... more
Mysterious charge transport in self-assembled monolayer transistors unraveled
An international team of researchers from the Netherlands, Russia and Austria discovered that monolayer coverage and channel length set the mobility in self-assembled monolayer field-effect transistors (SAMFETs). This opens the door to extremely sensitive chemical sensors that can be produc ... more
Philips and Concateno Announce Revolutionary Drugs-of-Abuse Testing System
Concateno plc, provider of drug and alcohol testing programmes, and Royal Philips Electronics have announced an innovative handheld drugs-of-abuse detection device. Concateno-Philips pioneering system will make testing for drugs such as cocaine and heroin quicker, simpler and easier enabli ... more
